# Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis

> **NCT04545788** · NA · UNKNOWN · sponsor: **Beijing Chest Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.

## Key facts

- **NCT ID:** NCT04545788
- **Lead sponsor:** Beijing Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04545788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04545788, "Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04545788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*